ExCulture is proud to announce that we have been awarded the newly established Health Holland TKI-MKB Public-Private Partnership fund. Our project, in collaboration with Leiden University Medical Center – Center for Proteomics and Metabolomic (LUMC-CPM), Good Biomarker Sciences (GBS), and Erasmus Medical Center (EMC), aims to revolutionise the production of an animal-free, alternative heparin. To learn more about our research plan check out the summary on the Health Holland website.
You can also check out this article (March 2024) where Health Holland interviewed ExCulture’s Co-founders about their experience as applicants to the pilot call. CSO Ilaria Poledri highlighted that “The subsidy from the SME call comes at a great timing, it will generate a lot of progress and increase our understanding of this animal-free, alternative heparin” while CEO Aisling Foley concluded; “We hope that in the near future, all of this [research] will have helped us get another step closer to replacing heparin derived from animals”.
